TY - JOUR T1 - Analytical sensitivity of seven SARS-CoV-2 antigen-detecting rapid tests for Omicron variant JF - medRxiv DO - 10.1101/2021.12.18.21268018 SP - 2021.12.18.21268018 AU - Meriem Bekliz AU - Kenneth Adea AU - Catia Alvarez AU - Manel Essaidi-Laziosi AU - Camille Escadafal AU - Laurent Kaiser AU - Isabella Eckerle Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/12/22/2021.12.18.21268018.abstract N2 - The emergence of novel SARS-CoV-2 variants of concern (VOCs) requires investigation of a potential impact on diagnostic performance, such as Antigen-detecting rapid diagnostic tests (Ag-RDT). Although anecdotal reports have been circulating that Omicron is in principle detectable by Ag-RDTs, no published data are a yet available for the newly emerged Omicron variant. Here, we have performed an analytical sensitivity testing with cultured virus in seven Ag-RDTs for their sensitivity to Omicron compared to data earlier obtained on VOCs Alpha, Beta, Gamma and Delta and a pre-VOC isolate of SARS-CoV-2. Overall, we have found a tendency towards lower sensitivity for Omicron compared to pre-VOC SARS-CoV-2 and the other VOCs across tests. Importantly, while analytical testing with cultured virus may be a proxy for clinical sensitivity, is not a replacement for clinical evaluations which are urgently needed for Ag-RDT performance in Omicron-infected individuals.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Swiss National Science Foundation (grant number 196383), the Fondation Ancrage Bienfaisance du Groupe Pictet, and FIND, the global alliance for diagnostics. The Swiss National Science Foundation and the Fondation Ancrage Bienfaisance du Groupe Pictet had no role in data collection, analysis, or interpretation. Antigen rapid diagnostic tests were provided by FIND and FIND was involved in methodology, data analysis and interpretation. CE is an employee of FIND.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Use of anonymized left-over specimens from routine diagnostics are in accordance with a general informed consent of the University Hospitals of Geneva. The ethics committee of the University Hospitals of Geneva therefore waived a separate ethical approval beyond the already existing general informed consent for this particular study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors ER -